Search
Now showing items 1-5 of 5
TGF-ß1-Licensed Murine MSCs show superior therapeutic efficacy in modulating corneal allograft immune rejection In Vivo
(Elsevier, 2020-05-29)
Mesenchymal stromal cells (MSCs) are a promising therapeutic option for multiple immune diseases/disorders; however, efficacy of MSC treatments can vary significantly. We present a novel licensing strategy to improve the ...
Human monocyte subset distinctions and function: Insights from gene expression analysis
(Frontiers Media, 2020-06-04)
Monocytes are a highly plastic innate immune cell population that displays significant heterogeneity within the circulation. Distinct patterns of surface marker expression have become accepted as a basis for distinguishing ...
Editorial: Innovative biologics and drugs to target renal inflammation
(Frontiers Media, 2020-02-06)
[No abstract available]
Mesenchymal stromal cell–based therapies for acute kidney injury: progress in the last decade
(Elsevier, 2020-01-28)
A little over 10 years ago, the therapeutic potential of mesenchymal stromal cells (MSCs) for the treatment of acute kidney injury (AKI) was becoming widely recognized. Since then, there has been further intensive study ...
Effects of mesenchymal stromal cells on regulatory T cells: Current understanding and clinical relevance
(AlphaMed Press and Wiley, 2020-01-29)
The immunomodulatory potential of mesenchymal stromal cells (MSCs) and regulatory T cells (T-reg) is well recognized by translational scientists in the field of regenerative medicine and cellular therapies. A wide range ...